Kappa BioSciences Starts Ops

OSLO, NorwayKappa BioScience AS formally commenced corporate operations, with plans to market menaquinone, vitamin K2, produced using a proprietary technology, to the European and North American markets. The all-trans vitamin K product will be marketed as K2VITAL in both powder and oil forms. Kappa BioScience also developed an assay and quality testing method for vitamin K2 MK7, which will allow customers to verify they are receiving a quality product that will meet label claims.

We are very excited to move from research to application, bringing this new, soy-free and highly purified Vitamin K product to the human nutrition market for use in foods and dietary supplements" said Egil Greve, CEO, who will head the companys operations out of its Oslo, Norway headquarters. Our team has been focused over the past two years using cutting edge technology to produce and qualify the best possible Vitamin K product available."

The privately-held company further plans to launch additional products into the food, nutraceutical and pharma markets.